[ad_1]
Sometime in 2021, however, there was a new way to quickly carry out this research by turning the idea into a well-paying company that is now Altos. The effort was made under the direction of Richard Klausner, a former director of the National Cancer Institute and now a businessman. Klausner, who previously helped set up companies like Juno Therapeutics and a cancer testing company Darkness, is known for making large, and profitable bets on new technologies.
According to a joint venture in the UK at Altos Labs, Klausner is the CEO of the new company. Klausner did not respond when attempted to contact him via email or phone. Like Milner, he also lives in Los Altos Hills.
A number of developers are beginning to refine the technology, including Life Biosciences, Turn Biotechnologies, AgeX Therapeutics, and Shift Bioscience in the UK, although the experiment has not resulted in human clinical trials being tested in clinical trials.
“There are hundreds of millions of dollars that are being spent on recycling, especially for the purpose of rejuvenating the limbs,” said David Sinclair, a Harvard University researcher who last December reports Restore the mouse using this method.
Sinclair describes the garden as “nascent” but thinks he has a special promise. “What else can you do that would change the age of the body?” he says. “In my lab we are cutting out major organs and nerves, such as skin, muscles and brain, to see what we can repair.” Sinclair says he is not interested in Altos but spoke at the 2020 conference and asked for an award from the Milky Way.
Business science
Altos has not yet announced this, but it was merged with Delaware this year and a disclosure held in California in June shows the company has raised $ 270 million, according to Will Gornall, a professor of business at the University of British Columbia who analyzed the document. In addition to Bezos and Milner, the company is also home to some of the richest professionals in the world.
Other works by Altos and Peter Walter, whose laboratory at the University of California, San Francisco, is behind a molecule that shows interest in memory. Participant is Wolf Reik, a rehabilitation specialist who recently resigned as director of the Babraham Institute in the UK after the site. He said he was working with “another research organization” which is now believed to be Altos. Walter and Reik declined to comment.
Initially, Altos will provide funding to researchers who do not immediately expect sales or revenue. According to one person described by Klausner and Milner, the company’s initial innovations will be “great science.”
Altos attracts university professors by offering them $ 1 million a year or more, including justice, and the right to work hard to solicit donations. Another researcher who confirmed receiving a job from Altos, Manuel Serrano of the Institute for Research in Biomedicine, in Barcelona, Spain, said the company would pay him five or ten times more than what he receives here.
“The wisdom of Altos Labs is to conduct research based on interest. This is what I do and I love to do, “says Serrano, who wants to travel to Cambridge, UK to join Altos. In this case, through a business company, we have the right to be bold and research.
Any treatment for chronic illness can be billions, but Altos does not rely on making money in the first place. “The goal is to understand reform,” Serrano said. “I would say the idea of making money in the future exists, but it’s not a real goal at the moment.”
[ad_2]
Source link
